耐药及敏感卵巢癌组织与细胞系中microRNA的表达及意义  

Expression and Significance of microRNA in Chemoresistant and Sensitive Ovarian Cancer Tissue and Cell Lines

作　　者：周莹莹[1] 王敏[1] 吴建磊[1] 接智慧[1] 常爽[1] 双婷[1] 

机构地区：[1]中国医科大学附属盛京医院,辽宁沈阳110004

出　　处：《肿瘤学杂志》2014年第3期197-202,共6页Journal of Chinese Oncology

摘　　要：[目的]探讨miR-1307的差异表达对卵巢癌紫杉醇耐药性的影响。[方法]Realtime PCR方法研究20例化疗耐药卵巢癌与20例化疗敏感卵巢癌组织及耐药与敏感卵巢癌细胞系(SKOV3-TR30和SKOV3)中miR-1307的表达情况;生物信息学方法预测miR-1307可能的靶基因及其靶基因的GO功能分析及通路分析。[结果]miR-1307在化疗耐药卵巢癌组织及细胞系中表达水平显著高于敏感组织及细胞系中,并且具有显著性(P<0.05,P<0.0001),其表达与卵巢癌患者绝经与否、手术病理分期、组织学分级及有无淋巴结转移无明显相关性(P>0.05);通过生物信息学分析,miR-1307的预测靶基因共124个,可能参与的生物学过程461个,分子功能80个,参与的信号通路15个。[结论]miR-1307与卵巢癌化疗耐药有关,可能通过相关的靶基因及其参与的生物学过程调节卵巢癌耐药。[Purpose] To investigate the influence of differentiation expression of miR-1307 on paclitaxel（PTX） resistance in ovarian cancer. [Methods] Quantitative real-time PCR was used to verify the expression of miR-1307 in 20 cases of PTX-resistant and 20 cases of PTX-sensitive ovarian cancer specimens and cell lines（SKOV3-TR30 and SKOV3）. Bioinformatics methods were used to predict the potential targets of miR-1307 and to implement the Gene ontology（GO） and pathway enrichment analysis. [ Results ] PTX-resistant ovarian cancer specimens and cell line expressed obviously higher level of miR-1307 than the sensitive ones,with statistical significance（P＆lt;0.05,P＆lt;0.0001）. And there was no obvious correlation between the expression of miR-1307 and the factors of biological behaviors,including menopause,surgical pathologic stage,histological grade,and lymph node metastasis（P＆gt;0.05）. There were 124 potential target genes of miR-1307. They were likely to take part in 461 biological process,80 molecular function and 15 signaling pathway.[Conclusion] ΜiR-1307 might relate to the chemoresistance of ovarian cancer. It can regulate the chemoresistance of ovarian cancer by targeting its target genes.

关 键 词：miR-1307 卵巢癌 基因芯片 化疗耐药 生物信息学 靶基因 

分 类 号：R737.31[医药卫生—肿瘤]